Quick Answer
INTEGRATED BIOPHARMA INC reported Gross Profit of $5.56 million for the year ending 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +43.2% in Gross Profit from 2024 to 2025.
- This data is from INTEGRATED BIOPHARMA INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2010: $806.0 thousand | Q1 2011: $2.06 million | Q3 2011: $2.75 million | Q4 2011: $2.49 million | Q1 2012: $1.34 million | Q3 2012: $1.57 million | Q4 2012: $1.14 million | Q1 2013: $1.24 million | Q3 2013: $1.60 million | Q4 2013: $1.47 million | Q1 2014: $727.0 thousand | Q3 2014: $1.30 million | Q4 2014: $1.26 million | Q1 2015: $899.0 thousand | Q3 2015: $1.32 million | Q4 2015: $975.0 thousand | Q1 2016: $1.32 million | Q3 2016: $2.15 million | Q4 2016: $1.47 million | Q1 2017: $1.34 million | Q3 2017: $1.01 million | Q4 2017: $1.05 million | Q1 2018: $1.47 million | Q3 2018: $1.22 million | Q4 2018: $1.33 million | Q1 2019: $2.09 million | Q3 2019: $1.40 million | Q4 2019: $2.03 million | Q1 2020: $1.85 million | Q3 2020: $2.37 million | Q4 2020: $2.17 million | Q1 2021: $2.66 million | Q3 2021: $1.42 million | Q4 2021: $1.75 million | Q1 2022: $1.98 million | Q3 2022: $997.0 thousand | Q4 2022: $1.07 million | Q1 2023: $1.01 million | Q3 2023: $832.0 thousand | Q4 2023: $520.0 thousand | Q1 2024: $1.25 million | Q3 2024: $1.37 million | Q4 2024: $1.17 million | Q1 2025: $1.55 million | Q3 2025: $1.02 million | Q4 2025: $29.0 thousand.
- Over the full 15 years of available data (2011 to 2025), INTEGRATED BIOPHARMA INC's Gross Profit has declined by 45.3%.
- Historical annual values: Fiscal year 2025: $5.56 million | Fiscal year 2024: $3.88 million | Fiscal year 2023: $4.06 million | Fiscal year 2022: $6.55 million | Fiscal year 2021: $9.48 million | Fiscal year 2020: $6.73 million | Fiscal year 2019: $6.22 million | Fiscal year 2018: $4.99 million | Fiscal year 2017: $6.67 million | Fiscal year 2016: $5.50 million | Fiscal year 2015: $4.39 million | Fiscal year 2014: $4.88 million | Fiscal year 2013: $5.50 million | Fiscal year 2012: $7.61 million | Fiscal year 2011: $10.16 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: